PURPOSE: To examine the feasibility and potential of magnetic fluid hyperthermia (MFH) as a minimally invasive method for hyperthermia treatment of prostate cancer. MATERIALS AND METHODS: Orthotopic Dunning R3327 prostate tumors were induced in 20 male Copenhagen rats. The animals either received MFH treatment following intratumoral administration of magnetic fluids or were used as either tumor growth controls for determination of iron distribution in selected organs or as histologic controls without MFH treatment. The MFH treatments were carried out at 45 degrees C or 50 degrees C using an AC magnetic field applicator system designed for small animals. RESULTS: Sequential treatments with MFH were possible following a single intratumoral injection of magnetic fluid. Intratumoral temperatures of 50 degrees C and more were obtained and were monitored online using fluoro-optic thermometry. Four days after MFH treatments, 79% of the injected dose of ferrites was still present in the prostate. CONCLUSIONS: The successful intraprostatic nanoparticle infiltration and stable steady-state intratumoral treatment temperatures demonstrate the feasibility of MFH in a prostate cancer model. Efficacy and survival benefit must be confirmed in further experiments.
PURPOSE: To examine the feasibility and potential of magnetic fluid hyperthermia (MFH) as a minimally invasive method for hyperthermia treatment of prostate cancer. MATERIALS AND METHODS: Orthotopic Dunning R3327 prostate tumors were induced in 20 male Copenhagen rats. The animals either received MFH treatment following intratumoral administration of magnetic fluids or were used as either tumor growth controls for determination of iron distribution in selected organs or as histologic controls without MFH treatment. The MFH treatments were carried out at 45 degrees C or 50 degrees C using an AC magnetic field applicator system designed for small animals. RESULTS: Sequential treatments with MFH were possible following a single intratumoral injection of magnetic fluid. Intratumoral temperatures of 50 degrees C and more were obtained and were monitored online using fluoro-optic thermometry. Four days after MFH treatments, 79% of the injected dose of ferrites was still present in the prostate. CONCLUSIONS: The successful intraprostatic nanoparticle infiltration and stable steady-state intratumoral treatment temperatures demonstrate the feasibility of MFH in a prostate cancer model. Efficacy and survival benefit must be confirmed in further experiments.
Authors: Fengqin Hu; Keith W Macrenaris; Emily A Waters; Elise A Schultz-Sikma; Amanda L Eckermann; Thomas J Meade Journal: Chem Commun (Camb) Date: 2009-10-14 Impact factor: 6.222
Authors: Andreas Jordan; Regina Scholz; Klaus Maier-Hauff; Frank K H van Landeghem; Norbert Waldoefner; Ulf Teichgraeber; Jens Pinkernelle; Harald Bruhn; Fabian Neumann; Burghard Thiesen; Andreas von Deimling; Roland Felix Journal: J Neurooncol Date: 2005-11-29 Impact factor: 4.130
Authors: Fengqin Hu; Keith W MacRenaris; Emily A Waters; Taiyang Liang; Elise A Schultz-Sikma; Amanda L Eckermann; Thomas J Meade Journal: J Phys Chem C Nanomater Interfaces Date: 2009-12-10 Impact factor: 4.126
Authors: Anastasia K Hauser; Robert J Wydra; Nathanael A Stocke; Kimberly W Anderson; J Zach Hilt Journal: J Control Release Date: 2015-09-25 Impact factor: 9.776
Authors: Mustafa Raoof; Stuart J Corr; Warna D Kaluarachchi; Katheryn L Massey; Katrina Briggs; Cihui Zhu; Matthew A Cheney; Lon J Wilson; Steven A Curley Journal: Nanomedicine Date: 2012-02-17 Impact factor: 5.307